Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - HARROW HEALTH, INC. | a54103exv99w1.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 26, 2009
TRANSDEL PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | 000-52998 | 45-0567010 | ||
(State of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
4225 Executive Square, Suite 485, La Jolla, California (Address of Principal Executive Offices) |
92037 (Zip Code) |
Registrants telephone number, including area code: (858) 457-5300
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
WEST\21818972.1
Item 7.01. Regulation FD Disclosure.
On Monday, October 26, 2009, Dr. Juliet Singh, Transdel Pharmaceutical, Inc.s President and
Chief Executive Officer, will be presenting at the 4th Annual BIOCOM Investor Conference held at
the Hyatt Regency Hotel in La Jolla, California. Dr. Singh will also be presenting at the 8th
Annual BIO Investor Forum held at the Palace Hotel in San Francisco, California on Thursday,
October 29, 2009. A copy of Dr. Singhs presentation, which provides information regarding
Transdels Phase 3 clinical trial results for its lead topical pain drug Ketotransdel®, is attached
as Exhibit 99.1 to this Current Report on Form 8-K and will be shown at both conferences.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No. | Description | |
99.1
|
Presentation for both the 4th Annual BIOCOM Investor Conference, to be held at the Hyatt Regency Hotel in La Jolla, California on October 26, 2009 and the 8th Annual Bio Investors Forum, to be held at the Palace Hotel in San Francisco, California on October 29, 2009. |
WEST\21818972.1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: October 26, 2009
TRANSDEL PHARMACEUTICALS, INC. |
||||
By: | /s/ John T. Lomoro | |||
John T. Lomoro | ||||
Chief Financial Officer | ||||
WEST\21818972.1
EXHIBIT INDEX
Exhibit No. | Description | |
99.1
|
Presentation for both the 4th Annual BIOCOM Investor Conference, to be held at the Hyatt Regency Hotel in La Jolla, California on October 26, 2009 and the 8th Annual Bio Investors Forum, to be held at the Palace Hotel in San Francisco, California on October 29, 2009. |
WEST\21818972.1